Sequential anaphylaxis and delayed rituximab-induced serum sickness with skin testing findings: a case report.
A complex hypersensitivity reaction pattern to rituximab adds clinical insights for managing immune responses to anti-cancer antibodies.
This case report describes a lymphoma patient who experienced sequential anaphylaxis followed by delayed serum sickness reaction to rituximab, with skin testing findings that can inform clinical management of rituximab hypersensitivity. The case adds to the small literature on complex multi-phase hypersensitivity reactions to anti-CD20 therapy.
What the study was
- Study design
- case_report
- Category
- drug safety / hematological oncology
- Maturity
- Exploratory
- Journal
- Allergy, Asthma, and Clinical Immunology
Why it surfaced
Single-case safety report for rituximab hypersensitivity. Minimal novelty; rituximab anaphylaxis management is well-described. Captured because of lymphoma context in T1 hematologic malignancies query. Conservative case-report cap applied.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.